Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

Brock University

$31,060.00

Design of cyclic oligonucleotide analogues as mucosal vaccine adjuvants

FY 2011-12

Summary
3',5'-Cyclic diguanylic acid (cdiGMP) is a small cyclic nucleic acid molecule that is important in regulating bacterial density, and it is emerging as an important bacterial messenger in regulating phenomena that occur on bacterial cell surface. This chemical is also found to enhance the immune response when used as an additive in immunotherapy. It is proposed that certain chemically modified cdiGMP compounds are effective additives in promoting immune response of vaccines. With certain modifications of the chemical structure, the associated side effects of cdiGMP, such as toxicity, can be reduced. Therefore these modified cdiGMP, when used as an additive with vaccines, will help combat the emerging and re-emerging infectious and inflammatory diseases.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
395519-2009
Name nom
Yan, Hongbin
Department département
Chemistry
Organization id
22
Institution établissement
Brock University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2009
Award amount
31060
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
2
Nb partie
3
Application title
Design of cyclic oligonucleotide analogues as mucosal vaccine adjuvants
Keyword
NSERC
Application summary
3',5'-Cyclic diguanylic acid (cdiGMP) is a small cyclic nucleic acid molecule that is important in regulating bacterial density, and it is emerging as an important bacterial messenger in regulating phenomena that occur on bacterial cell surface. This chemical is also found to enhance the immune response when used as an additive in immunotherapy. It is proposed that certain chemically modified cdiGMP compounds are effective additives in promoting immune response of vaccines. With certain modifications of the chemical structure, the associated side effects of cdiGMP, such as toxicity, can be reduced. Therefore these modified cdiGMP, when used as an additive with vaccines, will help combat the emerging and re-emerging infectious and inflammatory diseases.